Barclays Reinstated Boardwalk Pipeline Partners (BWP) at Equalweight
Get Alerts BWP Hot Sheet
Price: $12.05 --0%
Rating Summary:
3 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays reinstated coverage on Boardwalk Pipeline Partners (NYSE: BWP) with a Equalweight. PT $29.00.
"We believe the newly completed acquisition of PL Midstream provides an entry point for the partnership into NGL/olefin storage/transportation and diversifies its asset base, which was primarily exposed only to natural gas transportation and storage prior to the transaction," the analyst said. "We expect the company to leverage the newly purchased assets with bolt-on projects and expansions, which should better position BWP to resume cash distribution increases in the future."
For an analyst ratings summary and ratings history on Boardwalk Pipeline Partners click here. For more ratings news on Boardwalk Pipeline Partners click here.
Shares of Boardwalk Pipeline Partners closed at $26.92 yesterday.
"We believe the newly completed acquisition of PL Midstream provides an entry point for the partnership into NGL/olefin storage/transportation and diversifies its asset base, which was primarily exposed only to natural gas transportation and storage prior to the transaction," the analyst said. "We expect the company to leverage the newly purchased assets with bolt-on projects and expansions, which should better position BWP to resume cash distribution increases in the future."
For an analyst ratings summary and ratings history on Boardwalk Pipeline Partners click here. For more ratings news on Boardwalk Pipeline Partners click here.
Shares of Boardwalk Pipeline Partners closed at $26.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share